Industry · Healthcare & Life Sciences
Healthcare strategy where regulatory context determines everything.
Pharma portfolio intelligence. MedTech market entry. GCC government health authority advisory. We've done primary research and strategic advisory for global pharma players and emerging health tech companies.
Healthcare & Life Sciences in 2026.
The GCC healthcare market is being reshaped by Vision 2030 health system transformation across Saudi Arabia, combined with Abu Dhabi's ambition to become a regional medical hub. Government health entities are upgrading procurement processes, bringing in private sector operators, and investing in health technology at a pace not seen before.
In India, the pharma sector is navigating post-pandemic supply chain reconfiguration, pricing pressure, and a regulatory environment that is tightening for both domestic and export markets. Global pharma companies with India manufacturing partnerships are reassessing their exposure.
We've done portfolio intelligence work for Abbott and GSK in this market – research that required 60+ KOL interviews across therapeutic areas. We know how to navigate the regulatory landscape and who to talk to.
Healthcare clients we've worked with.
Sector signals – 2026
$75B
GCC healthcare market size by 2025, growing at 8% annually
$25B+
India pharma exports annually – 3rd largest globally by volume
60+
KOL interviews completed per typical pharma portfolio mandate
50+
hospital chains actively expanding operations across GCC
Challenges we solve in Healthcare & Life Sciences.
Regulatory navigation across three systems
MOHAP (UAE), SFDA (Saudi Arabia), and CDSCO (India) are three fundamentally different regulatory systems. Most companies approach them with a single-track strategy and pay for it in approval delays of 12–24 months.
Market access for pharma products
Pricing, reimbursement, and formulary positioning in GCC government health systems are market entry decisions, not afterthoughts. Getting them wrong at launch is costly and difficult to reverse.
Hospital chain expansion strategy
Site selection, demand forecasting, operational model, and local partnership structure determine the viability of hospital chain expansion into new city tiers or new countries. Each variable requires primary research.
Digital health adoption curves
Tech-led health models face different trust barriers, workflow integration challenges, and procurement processes than general enterprise software. Government and private hospital procurement timelines are 18–36 months.
Medical device distribution and registration
Distributor qualification, import regulations, tender strategy, and in-country registration requirements differ significantly between India, UAE, Saudi Arabia, and Southeast Asian markets.
KOL and clinical intelligence
Understanding the clinical opinion leader landscape, therapeutic area dynamics, and prescriber behaviour in a new market requires 40–80 structured interviews – not survey panels or secondary research.
Who we work with in Healthcare & Life Sciences.
Global pharma companies entering GCC or Southeast Asia
Conducting portfolio intelligence, market access assessment, or full market entry execution – requiring deep KOL networks, regulatory expertise, and primary research capability.
Hospital chains building international expansion strategy
Evaluating new geographies for organic expansion or acquisition – requiring site-level feasibility, demand forecasting, and operational model assessment in unfamiliar markets.
Medical device companies navigating distributor networks
Entering India, GCC, or Southeast Asian markets – requiring distributor identification, regulatory mapping, and tender intelligence across highly fragmented procurement landscapes.
Digital health startups seeking enterprise or government clients
Selling into hospital chains, government health authorities, or insurer networks – requiring buyer research, ICP validation, and a GTM approach calibrated for long health sector sales cycles.
Not sure which engagement fits your situation? Take our free 2-minute business diagnostic →
Country and sector guides
Browse all our Healthcare & Life Sciences market entry guides by geography and sector.
Market intelligence, delivered weekly.
GreyRadius research notes, market entry signals, and sector briefs – delivered weekly. No fluff.
Healthcare or pharma mandate?
We understand the regulatory context. Tell us your question.